Gyre Therapeutics (GYRE) to Release Earnings on Tuesday

Gyre Therapeutics (NASDAQ:GYRE) is expected to be releasing its Q4 2025 results before the market opens on Tuesday, March 31st. Analysts expect Gyre Therapeutics to post earnings of $0.06 per share and revenue of $36.3030 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, March 19, 2026 at 4:00 PM ET.

Gyre Therapeutics (NASDAQ:GYRE) last posted its earnings results on Thursday, March 12th. The company reported $0.04 EPS for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.04). The firm had revenue of $37.20 million during the quarter, compared to analysts’ expectations of $36.30 million. Gyre Therapeutics had a return on equity of 10.85% and a net margin of 4.31%.

Gyre Therapeutics Price Performance

NASDAQ GYRE opened at $7.04 on Tuesday. The stock has a market capitalization of $682.60 million, a PE ratio of 704.70 and a beta of 1.97. The business has a 50 day simple moving average of $7.92 and a two-hundred day simple moving average of $7.75. Gyre Therapeutics has a 1-year low of $6.11 and a 1-year high of $11.78.

Institutional Investors Weigh In On Gyre Therapeutics

Several institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC boosted its holdings in shares of Gyre Therapeutics by 13.0% in the 4th quarter. Geode Capital Management LLC now owns 423,222 shares of the company’s stock worth $2,989,000 after purchasing an additional 48,602 shares during the period. State Street Corp raised its holdings in Gyre Therapeutics by 10.7% during the 4th quarter. State Street Corp now owns 202,225 shares of the company’s stock valued at $1,428,000 after buying an additional 19,472 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in Gyre Therapeutics by 37.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 169,158 shares of the company’s stock valued at $1,194,000 after buying an additional 45,772 shares during the period. Millennium Management LLC bought a new stake in Gyre Therapeutics in the third quarter worth $267,000. Finally, Goldman Sachs Group Inc. boosted its stake in Gyre Therapeutics by 72.5% during the fourth quarter. Goldman Sachs Group Inc. now owns 31,108 shares of the company’s stock worth $220,000 after buying an additional 13,074 shares during the period. 23.99% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the company. Zacks Research cut Gyre Therapeutics from a “hold” rating to a “strong sell” rating in a report on Monday, March 16th. Wall Street Zen cut shares of Gyre Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, March 14th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Gyre Therapeutics in a research note on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $17.00.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.